TW202237626A - Sars-cov-2免疫顯性肽構築體及其用途 - Google Patents

Sars-cov-2免疫顯性肽構築體及其用途 Download PDF

Info

Publication number
TW202237626A
TW202237626A TW110142318A TW110142318A TW202237626A TW 202237626 A TW202237626 A TW 202237626A TW 110142318 A TW110142318 A TW 110142318A TW 110142318 A TW110142318 A TW 110142318A TW 202237626 A TW202237626 A TW 202237626A
Authority
TW
Taiwan
Prior art keywords
hla
peptide
mhc
cov
sars
Prior art date
Application number
TW110142318A
Other languages
English (en)
Chinese (zh)
Inventor
多瑪茲 庫拉
蓋賓 麥克比思
安德魯 P 費瑞蒂
Original Assignee
美商帝斯肯醫療公司
美商Ahs醫院公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商帝斯肯醫療公司, 美商Ahs醫院公司 filed Critical 美商帝斯肯醫療公司
Publication of TW202237626A publication Critical patent/TW202237626A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physiology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
TW110142318A 2020-11-12 2021-11-12 Sars-cov-2免疫顯性肽構築體及其用途 TW202237626A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063113024P 2020-11-12 2020-11-12
US63/113,024 2020-11-12

Publications (1)

Publication Number Publication Date
TW202237626A true TW202237626A (zh) 2022-10-01

Family

ID=81601698

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110142318A TW202237626A (zh) 2020-11-12 2021-11-12 Sars-cov-2免疫顯性肽構築體及其用途

Country Status (7)

Country Link
US (1) US20230398205A1 (cg-RX-API-DMAC7.html)
EP (1) EP4244630A4 (cg-RX-API-DMAC7.html)
JP (1) JP7895943B2 (cg-RX-API-DMAC7.html)
AR (1) AR124054A1 (cg-RX-API-DMAC7.html)
AU (3) AU2021323389B1 (cg-RX-API-DMAC7.html)
TW (1) TW202237626A (cg-RX-API-DMAC7.html)
WO (1) WO2022104002A2 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115785231A (zh) * 2021-09-10 2023-03-14 广东菲鹏生物有限公司 一种鉴别新冠突变型抗原的抗体、试剂及方法
CN120302989A (zh) * 2022-10-05 2025-07-11 帝斯肯医疗公司 Magea1免疫原性肽、识别magea1免疫原性肽的结合蛋白和其用途
AU2023241306B2 (en) * 2022-10-05 2024-10-03 Tscan Therapeutics, Inc. Prame immunogenic peptides, binding proteins recognizing prame immunogenic peptides, and uses thereof
WO2025202937A1 (en) 2024-03-26 2025-10-02 BioNTech SE Cancer vaccines

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1571909A4 (en) * 2002-10-03 2009-11-11 Idm Pharma Inc OPTIMIZED MULTIPOPOP CONSTRUCTS AND USES THEREOF
US20060257852A1 (en) * 2003-04-10 2006-11-16 Chiron Corporation Severe acute respiratory syndrome coronavirus
CA2523875A1 (en) * 2003-04-28 2004-11-11 Public Health Agency Of Canada Sars virus nucleotide and amino acid sequences and uses thereof
WO2004110349A2 (en) * 2003-05-14 2004-12-23 Siga Technologies, Inc. Sars t cell epitopes and methods for identifying same
US11608363B2 (en) * 2018-07-03 2023-03-21 Leidos, Inc Materials and methods for cell-free expression of vaccine epitope concatemers
BR112021023348A2 (pt) * 2019-05-21 2022-02-01 Esperovax Inc Vacinação oral à base de levedura
CA3143533A1 (en) * 2019-08-01 2021-02-04 Madhavan Nallani A method of eliciting an immune response by administering a population of polymersomes having an associated antigen together with a population of polymersomes having an associated adjuvant as well as compositions comprising the two populations of polymersome
HUE058338T2 (hu) * 2020-02-20 2022-07-28 Euroimmun Medizinische Labordiagnostika Ag Eljárás és reagensek SARS-COV-2 diagnózisára
TW202200199A (zh) * 2020-03-20 2022-01-01 美商百歐恩泰美國公司 冠狀病毒疫苗及使用方法
IT202000006754A1 (it) * 2020-03-31 2021-10-01 Diasorin S P A Saggi per la rivelazione di SARS-CoV-2
CR20220552A (es) * 2020-04-02 2023-01-17 Regeneron Pharma Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno
CN118490818A (zh) * 2020-04-22 2024-08-16 生物技术欧洲股份公司 冠状病毒疫苗
MX2022013945A (es) * 2020-05-06 2023-02-14 Molecular Partners Ag Nuevas proteinas de union a repeticiones de anquirina y sus usos.
CA3178115A1 (en) * 2020-05-19 2021-11-25 Roman YELENSKY Sars-cov-2 vaccines
CN111647054B (zh) * 2020-06-12 2021-12-03 上海祥耀生物科技有限责任公司 一种用于检测新型冠状病毒SARS-CoV-2抗体的试剂及其应用
CA3187028A1 (en) * 2020-06-17 2021-12-23 Tscan Therapeutics, Inc. Sars-cov-2 immunodominant peptides and uses thereof
EP4208193A4 (en) * 2020-09-01 2024-09-25 Helmholtz-Zentrum für Infektionsforschung GmbH MULTI-REGION VACCINES AND IMMUNOGENIC COMPOSITIONS, THEIR PRODUCTION METHODS AND THEIR USES

Also Published As

Publication number Publication date
WO2022104002A3 (en) 2022-06-23
AU2022204350B2 (en) 2024-05-16
JP7895943B2 (ja) 2026-07-28
US20230398205A1 (en) 2023-12-14
WO2022104002A2 (en) 2022-05-19
AU2022204350A1 (en) 2022-07-14
AU2024205749A1 (en) 2024-09-05
EP4244630A4 (en) 2025-05-21
EP4244630A2 (en) 2023-09-20
AU2021323389B1 (en) 2022-03-24
WO2022104002A9 (en) 2023-05-25
AR124054A1 (es) 2023-02-08
JP2023550094A (ja) 2023-11-30

Similar Documents

Publication Publication Date Title
US20230287079A1 (en) Binding proteins recognizing sars-cov-2 antigens and uses thereof
AU2022204350B2 (en) SARS-CoV-2 immunodominant peptide constructs and uses thereof
US20230241205A1 (en) Sars-cov-2 immunodominant peptides and uses thereof
US20230272049A1 (en) Binding proteins recognizing hpv16 e7 antigen and uses thereof
TW202340224A (zh) Magea1免疫原性肽、識別magea1免疫原性肽之結合蛋白及其用途
JP2024544903A5 (cg-RX-API-DMAC7.html)
US20240190931A1 (en) Magec2 immunogenic peptides, binding proteins recognizing magec2 immunogenic peptides, and uses thereof
US20250249039A1 (en) Prame immunogenic peptides, binding proteins recognizing prame immunogenic peptides, and uses thereof
KR20250099771A (ko) Magea1 면역원성 펩타이드, magea1 면역원성 펩타이드를 인식하는 결합 단백질 및 이의 용도
CN118510797A (zh) 识别hpv16 e7抗原的结合蛋白和其用途
WO2025217028A1 (en) Magec2 immunogenic peptides, binding proteins recognizing magec2 immunogenic peptides, and uses thereof
TW202523702A (zh) Magea1免疫原性肽、識別magea1免疫原性肽之結合蛋白及其用途
CN118613497A (zh) Magea1免疫原性肽、识别magea1免疫原性肽的结合蛋白和其用途
CN118382631A (zh) Magec2免疫原性肽、识别magec2免疫原性肽的结合蛋白及其用途